行情

RVNC

RVNC

Revance
NASDAQ

实时行情|Nasdaq Last Sale

15.99
-0.46
-2.80%
盘后: 15.99 0 0.00% 16:41 12/13 EST
开盘
16.35
昨收
16.45
最高
16.55
最低
15.40
成交量
89.11万
成交额
--
52周最高
22.19
52周最低
9.88
市值
8.09亿
市盈率(TTM)
-4.2226
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RVNC 新闻

  • Revance Therapeutics: The Real Threat To Abbvie's Dividend
  • Seeking Alpha - Article.12/05 15:53
  • Revance Therapeutics Reports Publication Of Pooled Results From Phase 3 Trials For Glabellar Lines In Journal Of American Academy Of Dermatology
  • Benzinga.12/05 13:06
  • Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology
  • Business Wire.12/05 13:00
  • Why Dynatrace, Revance Therapeutics, and Immunomedics Slumped Today
  • MotleyFool.com.12/04 21:33

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.08%

热门股票

名称
价格
涨跌幅

RVNC 简况

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.
展开

Webull提供Revance Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。